Apremilast retention rate in clinical practice: observations from an Italian multi-center study.
Apremilast
Drug retention rate
Psoriatic arthritis
Journal
Clinical rheumatology
ISSN: 1434-9949
Titre abrégé: Clin Rheumatol
Pays: Germany
ID NLM: 8211469
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
received:
25
04
2022
accepted:
15
06
2022
revised:
25
05
2022
pubmed:
8
7
2022
medline:
23
9
2022
entrez:
7
7
2022
Statut:
ppublish
Résumé
There are few real-world setting studies focused on apremilast effectiveness (i.e., retention rate) in psoriatic arthritis (PsA). The main aim of this retrospective observational study is the assessment of apremilast 3-year retention rate in real-world PsA patients. Moreover, the secondary objective is to report the reasons of apremilast discontinuation and the factors related to treatment persistence. In fifteen Italian rheumatological referral centers, all PsA consecutive patients who received apremilast were enrolled. Anamnestic data, treatment history, and PsA disease activity (DAPSA) at baseline were recorded. The Kaplan-Meier curve and the Cox analysis computed the apremilast retention rate and treatment persistence-related risk factors. A p-value < 0.05 was considered statistically significant. The 356 enrolled patients (median age 60 [interquartile range IQR 52-67] yrs; male prevalence 42.7%) median observation period was 17 [IQR 7-34] months (7218 patients-months). The apremilast retention rate at 12, 24, and 36 months was, respectively, 85.6%, 73.6%, and 61.8%. The main discontinuation reasons were secondary inefficacy (34% of interruptions), gastro-intestinal intolerance (24%), and primary inefficacy (19%). Age and oligo-articular phenotype were related to treatment persistence (respectively hazard ratio 0.98 IQR 0.96-0.99; p = 0.048 and 0.54 IQR 0.31-0.95; p = 0.03). Almost three-fifths of PsA patients receiving apremilast were still in treatment after 3 years. This study confirmed its effectiveness and safety profile. Apremilast appears as a good treatment choice in all oligo-articular PsA patients and in those ones burdened by relevant comorbidities. Key Points • Apremilast retention rates in this real-life cohort and trials are comparable. • The oligo-articular phenotype is associated with long-lasting treatment (i.e., 3 years). • No different or more prevalent adverse events were observed.
Identifiants
pubmed: 35796847
doi: 10.1007/s10067-022-06255-3
pii: 10.1007/s10067-022-06255-3
doi:
Substances chimiques
Anti-Inflammatory Agents, Non-Steroidal
0
Antirheumatic Agents
0
Thalidomide
4Z8R6ORS6L
apremilast
UP7QBP99PN
Types de publication
Journal Article
Multicenter Study
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
3219-3225Informations de copyright
© 2022. The Author(s), under exclusive licence to International League of Associations for Rheumatology (ILAR).
Références
Taylor W, Gladman D, Helliwell P et al (2006) Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54:2665–2673
doi: 10.1002/art.21972
Gossec L, Baraliakos X, Kerschbaumer A et al (2020) EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis 79:700–712
pubmed: 32434812
Kavanaugh A, Mease PJ, Gómez-Reino JJ et al (2014) Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis 73:1020–1026
doi: 10.1136/annrheumdis-2013-205056
Cutolo M, Myerson GE, Fleischmann RM et al (2016) A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial. J Rheumatol 43:1724–1734
doi: 10.3899/jrheum.151376
Edwards CJ, Blanco FJ, Crowley J et al (2016) Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3). Ann Rheum Dis 75:1065–1073
doi: 10.1136/annrheumdis-2015-207963
Mease PJ, Gladman DD, Gómez-Reino JJ et al (2020) Long-Term Safety and Tolerability of Apremilast Versus Placebo in Psoriatic Arthritis: A Pooled Safety Analysis of Three Phase III, Randomized, Controlled Trials. ACR Open Rheumatol 2:459–470
pubmed: 32710493
pmcid: 7437129
Abignano G, Fadl N, Merashli M et al (2018) Apremilast for the treatment of active psoriatic arthritis: a single-centre real-life experience. Rheumatology (Oxford) 57:578–580
doi: 10.1093/rheumatology/kex454
Favalli EG, Conti F, Atzeni F et al (2018) Comments on “Short-term reasons for withdrawal and adverse events associated with apremilast therapy for psoriasis in real-world practice compared with in clinical trials: A multicenter retrospective study.” J Am Acad Dermatol 79:e119–e120
doi: 10.1016/j.jaad.2018.07.052
Favalli EG, Conti F, Selmi C et al (2020) Retrospective evaluation of patient profiling and effectiveness of apremilast in an Italian multicentric cohort of psoriatic arthritis patients. Clin Exp Rheumatol 38:19–26
pubmed: 31074721
Schoels M, Aletaha D, Funovits J et al (2010) Application of the DAREA/DAPSA score for assessment of disease activity in psoriatic arthritis. Ann Rheum Dis 69:1441–1447
doi: 10.1136/ard.2009.122259
Healy PJ, Helliwell PS (2008) Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis. Arthritis Rheum 59:686–691
doi: 10.1002/art.23568
Porta S, Otero-Losada M, Kölliker-Frers RA et al (2020) Adipokines, Cardiovascular Risk, and Therapeutic Management in Obesity and Psoriatic Arthritis. Front Immunol 11:590749
doi: 10.3389/fimmu.2020.590749
Klingberg E, Bilberg A, Björkman S et al (2019) Weight loss improves disease activity in patients with psoriatic arthritis and obesity: an interventional study. Arthritis Res Ther 21:17–10
doi: 10.1186/s13075-019-1810-5
Papadavid E, Rompoti N, Theodoropoulos K et al (2018) Real-world data on the efficacy and safety of apremilast in patients with moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol 32:1173–1179
doi: 10.1111/jdv.14832
Wong TH, Sinclair S, Smith B et al (2017) Real-world, single-centre experience of apremilast for the treatment of moderate to severe psoriasis. Clin Exp Dermatol 42:675–676
doi: 10.1111/ced.13150
Gladman DD, Ye JY, Chandran V et al (2021) Oligoarticular vs Polyarticular Psoriatic Arthritis: A Longitudinal Study Showing Similar Characteristics. J Rheumatol 48:1824–1829
doi: 10.3899/jrheum.210434
Stekhoven D, Scherer A, Nissen MJ et al (2017) Hypothesis-free analyses from a large psoriatic arthritis cohort support merger to consolidated peripheral arthritis definition without subtyping. Clin Rheumatol 36:2035–2043
doi: 10.1007/s10067-017-3637-2
Mekhail C, Chouk M, Prati C et al (2020) Prognostic factors of good response to DMARDs in psoriatic arthritis: a narrative review. Expert Rev Clin Pharmacol 13:505–519
doi: 10.1080/17512433.2020.1758556
Schett G, Wollenhaupt J, Papp K et al (2012) Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 64:3156–3167
doi: 10.1002/art.34627
Ogdie A, Liu M, Glynn M et al (2021) Descriptive Comparisons of the Effect of Apremilast and Methotrexate Monotherapy in Oligoarticular Psoriatic Arthritis: The Corrona Psoriatic Arthritis/Spondyloarthritis Registry Results. J Rheumatol 48:693–697
doi: 10.3899/jrheum.191209
Lucchetti R, Ceccarelli F, Cipriano E et al (2021) Application of Ultrasound in the Assessment of Oligoarticular Psoriatic Arthritis Subset: Results from Patients Treated with Apremilast. Isr Med Assoc J 23:412–415
pubmed: 34251122